Literature DB >> 33993369

Circ-EGFR Functions as an Inhibitory Factor in the Malignant Progression of Glioma by Regulating the miR-183-5p/TUSC2 Axis.

Qingdong Guo1, Jun Guo2, Wei Liu1, Shijie Hu1, Xuean Hu1, Qianliang Wang3, Xiaofan Jiang4.   

Abstract

Circular RNAs (circRNAs) have pivotal functions in regulating diverse biological processes of human tumors, including glioma. Herein, a novel circRNA epidermal growth factor receptor (circ-EGFR, hsa_circ_0080223) was researched in glioma. The molecular expression levels were analyzed via quantitative real-time polymerase chain reaction (qRT-PCR). Cell Counting Kit-8 (CCK-8) and colony formation assays were conducted to assess cell proliferation. Apoptosis was analyzed using flow cytometry. Cell migration and invasion were examined via transwell assay. Interaction relations between targets were verified using dual-luciferase reporter assay. Tumor Suppressor Candidate 2 (TUSC2) protein expression was examined by Western blot. In vivo experiment was performed by establishing xenograft model in mice. The qRT-PCR showed the downregulation of circ-EGFR and TUSC2 but the upregulation of microRNA-183-5p (miR-183-5p) in glioma samples. In vitro assays revealed that circ-EGFR overexpression induced the repression of cell proliferation, migration, and invasion but the promotion of apoptosis. Circ-EGFR was identified as a sponge of miR-183-5p and circ-EGFR-mediated glioma progression inhibition was abolished by miR-183-5p downregulation. Additionally, miR-183-5p targeted TUSC2 and miR-183-5p inhibitor impeded the development of glioma by upregulating the expression of TUSC2. Furthermore, circ-EGFR could regulate the TUSC2 level by sponging miR-183-5p. Glioma growth in vivo was also reduced by circ-EGFR via targeting the miR-183-5p/TUSC2 axis. Altogether, our results suggested that circ-EGFR inhibited the malignant progression of glioma by regulating the levels of miR-183-5p and TUSC2. Circ-EGFR may be a useful therapeutic target to antagonize the glioma progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Circ-EGFR; Glioma; MiR-183-5p; TUSC2

Mesh:

Substances:

Year:  2021        PMID: 33993369     DOI: 10.1007/s10571-021-01099-y

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  4 in total

Review 1.  Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.

Authors:  Tadas Rimkus; Sherona Sirkisoon; Alexandra Harrison; Hui-Wen Lo
Journal:  Discov Med       Date:  2017-05       Impact factor: 2.970

2.  Circular RNA circ_0079593 promotes glioma development through regulating KPNA2 expression by sponging miR-499a-5p.

Authors:  Z Yang; C Li; X-Y Fan; L-J Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-01       Impact factor: 3.507

3.  Advances in circular RNAs and their role in glioma (Review).

Authors:  Yuhao Zhang; Xiaomeng Lin; Xiuchao Geng; Liang Shi; Qiang Li; Fulin Liu; Chuan Fang; Hong Wang
Journal:  Int J Oncol       Date:  2020-04-16       Impact factor: 5.650

4.  Circular RNA circMTO1 Suppresses RCC Cancer Cell Progression via miR9/LMX1A Axis.

Authors:  Kecheng Li; Cheng-Liang Wan; Yan Guo
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  4 in total
  2 in total

Review 1.  Roles of circular RNAs in regulating the development of glioma.

Authors:  Jianing Fan; Yangyang Wang; Xiao Liang; Fanlin Zhou; Shijie Li; Xiaoju Li; Yu Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-01       Impact factor: 4.553

2.  NEDD4 degrades TUSC2 to promote glioblastoma progression.

Authors:  Tadas K Rimkus; Austin B Arrigo; Dongqin Zhu; Richard L Carpenter; Sherona Sirkisoon; Daniel Doheny; Angelina T Regua; Grace L Wong; Sara Manore; Calvin Wagner; Hui-Kuan Lin; Guangxu Jin; Jimmy Ruiz; Michael Chan; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2022-02-12       Impact factor: 8.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.